Adults 40 to 69, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Shared Decision-makingPrimary· One month after audio-recorded visit
The Observing Patient Involvement (OPTION) Scale was used for the coding of the SDM. The total OPTION scale ranges from 0 to 48. Higher values on the scale mean higher patient involvement in the decision-making process.
Group
Value
95% CI
Intervention
12.54
± 11.0198
Usual Care
12.15
± 10.4026
Quality of Decision (QD)Secondary· Up to 24 weeks after the audio-recorded visit
The total QD score ranges from 0 to 100. Higher percentage scores mean higher quality of the decision made.
Group
Value
95% CI
Intervention
82.23
± 13.503
Usual Care
80.45
± 13.925
AcceptabilitySecondary· Through study completion, an average of 1 year
Participants complete a structured questionnaire to rate the acceptability of the enrollment process, study procedures, and their overall satisfaction with the study. The score ranges from 10 to 50. Higher scores mean higher acceptability of study procedures.
Group
Value
95% CI
Intervention
42.43
± 5.318
Usual Care
43.17
± 4.590
Preference-Congruent Decision MakingSecondary· Through study completion, an average of 1 year
The Intention-to-Screen score ranges from 0 to 1. Score = 0 means no intention to receive the PSA test while score = 1 means intention to receive the PSA test.
Preference-concordant decision making will be scored as 1 (POSITIVE) for those patients with Intention-to-Screen value = 1 who actually receive the PSA test during the study timeframe, or for those patients with Intention-to-Screen value = 0 who did not receive it.
Preference-concordant decision making will be scored as 0 (NEGATIVE) for those patients with Intention-to-Screen value = 1 who did not receive the PSA test during the study
Participants with Congruence Score = 1
Group
Value
95% CI
Intervention
36
Usual Care
40
Participants with Congruence Score = 0
Group
Value
95% CI
Intervention
24
Usual Care
13
Sponsor's own description
This behavioral clinical trial assesses the efficacy of a educational intervention to increase shared decision making about prostate-specific antigen (PSA)-based screening for prostate cancer among African American males. Half of participants will receive a multimedia educational intervention, while the other half will receive usual care.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)
· recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
· Phase 2
· recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer
· Phase 2
· recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris
· Phase 2
· recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate
· Phase 2, PHASE3
· recruiting
Other Xavier University of Louisiana. trials
Trials by the same sponsor.
NCT06530225 — Are Louisiana Pharmacists PrEPared? Implementing Training and an Active PrEP (Pre-Exposure Prophylaxis) Prescribing Surv
· not yet recruiting
NCT05676970 — Using a Telehealth and Shared Decision-Making Model to Address Preventative Medicine Strategies Among Communities in Lou
· NA
· recruiting
NCT05745376 — Addressing Disparities in Food Access Among Young Children in Louisiana: A Farm to ECE Approach
· NA
· completed
NCT04939506 — COVID-19 Vaccine Education at the Point of Testing to Increase Vaccine Uptake in Vulnerable Communities in SE Louisiana
· NA
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xavier University of Louisiana.
Last refreshed: 29 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03869216.